Appearing as a significant advance in the battle against obesity, the drug is generating considerable buzz. It combines properties of two recognized GLP-1 binding agonists, liraglutide, with an additional glucose-dependent hormonal component. Initial study results have demonstrated substantial body reduction in patients with excessive weight, pote